Abstracts tagged "outcomes and systemic sclerosis"

Abstract Number: 1736 • 2018 ACR/ARHP Annual Meeting
Incidence and Risk Factors for Gangrene in Patients with Systemic Sclerosis from the Eustar Cohort
Carina Mihai^1,2, Oliver Distler¹, Ana Maria Gheorghiu^2,3, Paul Iulian Constantin², Rucsandra Dobrota^1,2, Suzana Jordan⁴, Vanessa Smith⁵, Eric Hachulla⁶, Joerg C. Henes⁷, Elise Siegert⁸, Serena Vettori⁹, Ulf Müller-Ladner¹⁰, Marco Matucci-Cerinic¹¹ and Yannick Allanore¹², ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Cantacuzino Hospital, Bucharest, Romania, ⁴Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, ⁷Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ⁸Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁹Rheumatology Unit, Department of Internal and Experimental Medicine University of Campania "Luigi Vanvitelli", Napoli, Italy, ¹⁰Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Bad Nauheim, Germany, ¹¹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹²Cochin Hospital, Paris Descartes University, Paris, France, Paris, France
Background/Purpose: In patients with systemic sclerosis (SSc), peripheral vasculopathy can promote critical ischemia and gangrene that are very severe complications with potential life-threatening consequences. Recently…
Abstract Number: 1875 • 2018 ACR/ARHP Annual Meeting
Influence of Setting an Upper Limit of the Modified Rodnan Skin Score As an Inclusion Criterion in Systemic Sclerosis Clinical Trials on the Ratio of Skin Fibrosis Progression Vs. Improvement – an Analysis of the Genisos Cohort
Carina Mihai^1,2, Rucsandra Dobrota^1,2, Shervin Assassi³, Maureen D. Mayes³ and Oliver Distler¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Recent studies on large cohorts of patients with systemic sclerosis (SSc) have shown that lowering the upper threshold of the modified Rodnan skin score…
Abstract Number: 1702 • 2017 ACR/ARHP Annual Meeting
Disease Progression in Systemic Sclerosis Patients with Concomittant or Isolated Interstitial Lung Disease and Pulmonary Arterial Hypertension in the Scleroderma Cohort Singapore
Maria Noviani¹, Seyed Ehsan Saffari², Sandra Mei Yu Kua¹, Grace Yin Lai Chan³, Gim Gee Teng⁴, Weng Giap Law⁵, Amelia Santosa⁴, Anita Yee Nah Lim⁴, Swee Cheng Ng¹ and Andrea Hsiu Ling Low¹, ¹Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, Singapore, ²Center for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore, Singapore, ³Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, SIngapore, Singapore, ⁴Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore, Singapore, ⁵Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore, Singapore
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are leading causes of mortality in patients with systemic sclerosis (SSc). We aimed to determine…
Abstract Number: 2620 • 2014 ACR/ARHP Annual Meeting
Mortality and Survival in Systemic Lupus Erythematosus Patients: Trends in a Spanish Cohort from 1985 to 2013
Sergi Heredia¹, Javier Narváez², Andrea Zacarias¹, Milagros Ricse¹, Gloria Albert¹, Eulalia Armengol¹, Helena Borrell¹, Olga Capdevila³, Francesca Mitjavila³, Toni Rozadilla¹, Xavier Juanola⁴ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: To study the mortality, survival and causes of death in a Spanish cohort of patients with systemic lupus erythematosus (SLE) over a 28-year period…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].